Shankar Musunuri, PhD, on Continuing Research With Gene Therapy in Inherited Retinal Diseases
The chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.
Shankar Musunuri, PhD, on Promising Efficacy Signals With Modifier Gene-Agnostic Therapy in Retinitis Pigmentosa
The chairman, chief executive officer, and cofounder of Ocugen discussed the recent data update on the company’s OCU400 program in inherited retinal diseases.
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy.